hVEGF基因防治血管成形术后再狭窄

目的 :观察人血管内皮生长因子 (h VEGF)基因对血管成形术后再狭窄的防治作用。 方法 :建立兔颈总动脉球囊损伤模型 ,以先期构建的真核表达质粒 pc DNA3/ h V EGF1 6 5 (5 0 0 μg,n=12 )和真核载体 pc DN A3(5 0 0 μg,n=12 )分别于血管腔内给药 ,给药后 2周、4周先行颈总动脉造影 ,再取材分别行 H- E、VB染色及 Northern blot分析。结果 :给药后 2周、4周颈总动脉造影示治疗组直径狭窄较对照组明显减少 ;病理检测示 2周、4周治疗组管腔狭窄率较对照组显著减轻 [(9.5 8± 1.35 ) % vs(31.72± 1.72 ) % ;(18.0 9± 2 .93) % vs (44 .0 5± 3.2 8) % ,P<0 .0 1];Northern blot分析显示 2周、4周治疗组特异性条带显色较对照组明显增强。 结论 :pc DNA3/ h VEGF1 6 5 裸质粒 DNA血管腔内给药能转染平滑肌细胞并持续表达至少 4周 ,促进了内皮细胞再生 ,减轻了血管成形术后再狭窄程度。

Gene therapy with human vascular endothelial growth factor in prevention of restenosis after angioplasty

Objective: To investigate the effect of human vascular endothelial growth factor on restenosis after angioplasty. Methods: A rabbit model of injured carotid artery was established using percutaneous transluminal angioplasty. The pcDNA3/hVEGF165（500 μg,n=12） and pcDNA3 （500 μg,n=12） were separately transfected into injured arterial wall with 30 min incubation. The carotid artery was imaged by arotic angiography at the end of week 2 and week 4. Pathology analysis and Northern blot analysis were performed for harvested injured artery segment. Results: Arotic angiography showed carotid artery diameter narrowness were obviously lessened at week 2 and week 4 in experimental group than that in control group; H-E stains showed lumina narrow ratio were obviously reduced at week 2 and week 4 in experimental group than that in control group［（9.58±1.35）% vs (31.72±1.72)%；(18.09±2.93)% vs (44.05±3.28)%， P<0.01 ］; By Northern blot analysis, the expression of hVEGF165mRNA in experimental group were upregulated than in contol group. Conclusion: pcDNA3/hVEGF165 can be transfected into smooth muscle cell and continue to secret bioactivity protein at least for 4 weeks; it can accelerate reendothelialization and prevent restenosis.